Press Releases
About Us
Executive Management
Board of Directors
Palatin Scientific Advisors
Careers at Palatin
Corporate Governance
Reporting Hotline
Research Focus
Clinical Pipeline
Our Focus: Peptide Drugs
Female Sexual Dysfunction
HSDD
Vyleesi License
Vyleesi
Phase 3 Reconnect Studies
Phase 2B Clinical Trial Results
Heart Failure
Inflammatory Disease
Obesity and Diabetes
Licensing & Collaboration
Investors
Overview
Press Releases
Event Calendar
Archived Events
Webcasts
SEC Filings
Analyst Coverage
Investor Resources
Resources
Corporate Presentation
Vyleesi™ (bremelanotide) for Hypoactive Sexual Desire Disorder (HSDD)
Poster Presentations
Female Sexual Dysfunction Related Videos: Expert Discussion
Scientific Publications
Patent Portfolio
Helpful Links
Contact Us
Contacting Palatin
Resources
Corporate Presentation
Palatin Technologies Corporate Presentation January 2019
